Micromet (MITI) surges 34% to $11.07, which is just above Amgen's (AMGN) $11/share offer for the company. More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/